Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
193 Colorectal Cancer Trials near Houston, TX
Power is an online platform that helps thousands of Colorectal Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerThis study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable).
Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either:
* mFOLFOX6 alone,
* mFOLFOX6 with bevacizumab, or
* mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Prior Systemic Therapy, Radiation, Neuropathy, Others
Must Not Be Taking:Anti-HER2 Therapy
400 Participants Needed
Duloxetine for Colorectal Cancer
Houston, Texas
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:25+
Key Eligibility Criteria
Disqualifiers:Peripheral Neuropathy, Seizure Disorder, Glaucoma, Others
Must Be Taking:Oxaliplatin
220 Participants Needed
This trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Hypertension, Heart Failure, Bleeding, Others
Must Not Be Taking:Thiazides, Corticosteroids, Lithium, Others
455 Participants Needed
Eflornithine + Sulindac for Colorectal Cancer Prevention
Houston, Texas
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:High Cardiovascular Risk, Uncontrolled Hypertension, Gastric/duodenal Ulcer, Others
Must Not Be Taking:Corticosteroids, NSAIDs, Anticoagulants
354 Participants Needed
Pumitamig + Chemotherapy for Colorectal Cancer
Houston, Texas
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiovascular Disease, Others
Must Not Be Taking:Checkpoint Inhibitors
990 Participants Needed
Amivantamab + FOLFIRI for Colorectal Cancer
Houston, Texas
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:ILD, Second Malignancy, HER2-positive, Others
Must Not Be Taking:Irinotecan, EGFR Agents, MET Agents
700 Participants Needed
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:ILD, Pneumonitis, Pulmonary Fibrosis, Others
Must Not Be Taking:EGFR Inhibitors, MET Inhibitors
1000 Participants Needed
ABBV-400 vs Standard Treatment for Colorectal Cancer
Houston, Texas
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused telisotuzumab adizutecan to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC).
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms as part of 2 stages. Each treatment arm in stage 1 receives a different dose of telisotuzumab adizutecan. Each treatment arm in stage 2 receives the optimal dose of telisotuzumab adizutecan or LONSURF plus bevacizumab. Up to approximately 460 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study in approximately 160 sites in 15-20 countries.
In stage 1, participants will receive intravenously (IV) infused telisotuzumab adizutecan dose A or B. In stage 2, participants will receive the optimal dose of IV infused telisotuzumab adizutecan or the standard of care (SOC), LONSURF oral tablets plus IV infused bevacizumab. The total study duration will be approximately 4 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Allergy To Bevacizumab, Active Infection, Others
Must Not Be Taking:C-MET Antibodies, ADCs
460 Participants Needed
MRTX849 + Cetuximab for Colorectal Cancer
Houston, Texas
This trial is testing a new treatment for patients with colorectal cancer. The treatment combines two drugs that work together to block cancer growth and prevent its spread. One of the drugs has shown promise in treating other types of cancer as well.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Active Brain Metastasis, Others
Must Not Be Taking:KRAS Inhibitors, Anti-EGFR
461 Participants Needed
Fruquintinib for Colorectal Cancer
Houston, Texas
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants.
Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Uncontrolled Hypertension, Cardiovascular Disease, Others
Must Not Be Taking:Anticoagulants, TKIs, CYP3A4 Inducers
78 Participants Needed
Vaccine Nous-209 for Lynch Syndrome
Houston, Texas
This trial tests the safety and effectiveness of the Nous-209 vaccine in patients with Lynch syndrome, a condition that increases cancer risk. The vaccine uses man-made proteins to help the immune system recognize and fight cancer cells. Researchers aim to see if the vaccine can prevent cancer development in these high-risk patients. Nous-209 is a ready-to-use cancer vaccine that targets specific markers found in certain types of tumors.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Cancer, HIV, Hepatitis, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants, NSAIDs, Others
45 Participants Needed
This phase Ib/II trial investigates the side effects and best dose of LY3214996 when given together with cetuximab alone or in combination with abemaciclib and to see how well they work in treating patients with colorectal cancer that cannot be removed by surgery (unresectable) and/or has spread to other places in the body (metastatic). Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. LY3214996 and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving LY3214996 and cetuximab alone or in combination with abemaciclib may help treat patients with colorectal cancer.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Brain Metastasis, Cardiovascular Disease, Infection, Others
Must Be Taking:Anti-EGFR Therapy
46 Participants Needed
Regorafenib + Lorigerlimab for Rectal Cancer
Houston, Texas
This is a prospective single-center, single-arm, open-label, phase II study evaluating the safety, activity, and efficacy of regorafenib in combination with lorigerlimab for the treatment of patients with regrowing or locally recurrent pMMR/MSS localized rectal cancer following TNT.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Autoimmune Disease, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants, Anticoagulants, Others
20 Participants Needed
Regorafenib + Lorigerlimab for Colorectal Cancer
Houston, Texas
To apply its findings as rationale needed for a subsequent registration trial towards a novel indication for systemic treatment of resectable, lung-limited metastatic CRC.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Extrapulmonary Metastases, Autoimmune Diseases, Others
Must Not Be Taking:Corticosteroids, Immunosuppressives, Anticoagulants, Others
30 Participants Needed
Regorafenib + Lorigerlimab for Colorectal Cancer
Houston, Texas
To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Cardiovascular Disease, Others
Must Not Be Taking:Immunosuppressants, Immune Checkpoint Inhibitors
16 Participants Needed
Ivonescimab for Colorectal Cancer
Houston, Texas
The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cardiac Impairment, Hypertension, Autoimmune, Others
Must Be Taking:PD-1/PD-L1 Inhibitors
90 Participants Needed
AMB-05X for Colorectal Cancer
Houston, Texas
To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Concurrent Malignancy, Hepatobiliary Disease, Autoimmune Disorders, Others
Must Not Be Taking:Tyrosine Kinase Inhibitors
15 Participants Needed
Adagrasib + Cetuximab + Cemiplimab for Colorectal Cancer
Houston, Texas
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Autoimmune Disease, Brain Metastases, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids, Proton Pump Inhibitors, Others
31 Participants Needed
AFNT-211 for Solid Tumors
Houston, Texas
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A\*11:01. The purpose of this study is to find the best dose of AFNT-211 that is safe and can shrink tumors in patients. AFNT-211 is an investigational therapy and this is the first time that AFNT-211 is being administered to patients. AFNT-211 is an autologous T cell product which means that it is made from a patient's own T cells. These cells are engineered and grown to recognize the KRAS G12V protein on the cell surface of cancer cells. AFNT-211 is infused into patients after a short course of lymphodepleting chemotherapy. Patients will frequently visit the study site. The doctors there will regularly check the size of the cancer and the patient's health. They will also take note of any unwanted effects. Patients may continue in this study for as long as they benefit from the treatment.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Primary Brain Tumor, Others
Must Not Be Taking:Cytotoxic Chemotherapy, Gene Therapy
100 Participants Needed
A2B530 CAR T Therapy for Solid Cancers
Houston, Texas
This trial tests A2B530, a treatment using modified immune cells from the patient, in adults with hard-to-treat cancers like colorectal, pancreatic, and lung cancer. The treatment aims to target and kill cancer cells while protecting healthy cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Local Therapy, Stem Cell Transplant, Organ Transplant, Others
160 Participants Needed
Why Other Patients Applied
"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."
FR
Lung Cancer PatientAge: 71
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."
EQ
Lung Cancer PatientAge: 70
"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."
OF
Cholangiocarcinoma PatientAge: 54
"I had two chemotherapy regÃmens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this trÃal. Thank you."
UM
Pancreatic Cancer PatientAge: 48
EO4010 for Colorectal Cancer
Houston, Texas
Open-label multicenter study
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disorders, HIV, Hepatitis, Others
Must Not Be Taking:Dexamethasone, Immunosuppressants, Immunostimulants, Others
42 Participants Needed
Cancer Vaccines for Lynch Syndrome
Houston, Texas
This trial tests a vaccine and an immune booster to prevent cancer in people with Lynch syndrome. The vaccine teaches the body to fight cancer, and the booster makes this process stronger. Vaccines have shown robust potential for preventing Lynch syndrome cancers.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, HIV, Hepatitis, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants, Others
186 Participants Needed
Amivantamab + Chemotherapy for Colorectal Cancer
Houston, Texas
This trial is testing a new medicine called amivantamab on patients with advanced colorectal cancer. The medicine helps the immune system find and destroy cancer cells. Researchers want to see how well it works alone and with standard chemotherapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:KRAS, NRAS, BRAF, EGFR, Others
225 Participants Needed
TAS-102 for Colorectal Cancer
Houston, Texas
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Malignancies, Electrolyte Imbalance, Severe Disorders, Others
25 Participants Needed
This phase II trial studies the effect of fecal microbiota transplant and re-introduction of anti-PD-1 therapy (pembrolizumab or nivolumab) in treating anti-PD-1 non-responders with colorectal cancer that has spread to other places in the body (metastatic). Fecal microbiota transplants contain the normal bacteria and viruses found in fecal (stool) material. Immunotherapy with monoclonal antibodies, such as pembrolizumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab or nivolumab with fecal microbiota transplants may help to control the disease.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Ileostomy, Colostomy, Autoimmune, Others
Must Be Taking:Anti-PD-1 Therapy
15 Participants Needed
BNT314 + BNT327 + Chemotherapy for Colorectal Cancer
Houston, Texas
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's immune system fight cancer in combination with another new treatment (BNT327, which is an immune checkpoint inhibitor) and chemotherapy in participants with metastatic colorectal cancer (mCRC).
This study will enroll participants with microsatellite stable or mismatch repair proficient (MSS/pMMR) mCRC who did not respond well to their first schema of chemotherapy. In one part of the study (i.e., Part B) mCRC participants will be enrolled, who have not received any systemic therapy before for their cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:MSI-H MCRC, Cardiovascular Disease, CNS Metastases, Autoimmune Disease, Others
Must Not Be Taking:Immune Checkpoint Inhibitors
482 Participants Needed
Telisotuzumab Adizutecan for Colorectal Cancer
Houston, Texas
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will receive SOC alone. Approximately 140 adult participants with CRC will be enrolled in the study in 45 sites worldwide.
In arm 1, participants will receive intravenous (IV) doses of telisotuzumab adizutecan alone. In arm 2 Participants will receive SOC alone. The study will run for a duration of approximately 51 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:No Tissue Sample, ILD, Others
140 Participants Needed
Drug Combination for Colorectal Cancer
Houston, Texas
To learn if the drug combination of BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab can help to control advanced or metastatic MSS-CRC.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune, Cardiovascular, Diabetes, Others
Must Not Be Taking:Steroids, Immunosuppressants, Others
40 Participants Needed
Novel Interventions for Colorectal Cancer
Houston, Texas
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Autoimmune Disorders, Hypertension, Others
120 Participants Needed
Drug Combination for Advanced Colorectal Cancer
Houston, Texas
To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Symptomatic Brain Metastasis, Cardiovascular Diseases, Active Infections, Others
Must Not Be Taking:ERK1/2, MEK, BRAF Inhibitors
33 Participants Needed
Know someone looking for new options?
Spread the word